Eupraxia Pharmaceuticals Inc
EPRX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$456.27M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $456.27 Million |
|---|---|
| Enterprise Value | $405.78 Million |
| Earnings per Share | $-1.03 |
| Beta | 1.5 |
| Outstanding Shares | 66,221,815 |
Return
| Return on Equity | -45.08% |
|---|---|
| Return on Assets | -42.30% |
| Return on Invested Capital | -47.52% |
Valuation & Multiples
| P/E Ratio | -6.7 |
|---|---|
| PEG | -10.24 |
| Price to Sales | - |
| Price to Book Ratio | 6.89 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.51 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$-0.26
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 37.43% |
|---|---|
| Total Invested | $233,217▼ 99.86% |
| Investors Holding | 3▼ 65.00% |
About Eupraxia Pharmaceuticals Inc
49 employees
CEO: James A. Helliwell
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical ...